Publications by authors named "Yong Gang Dai"
Article Synopsis
- The study aimed to assess how effective and safe etrolizumab is for treating inflammatory bowel disease (IBD) through a meta-analysis of randomized controlled trials.
- A total of five studies with 1,682 participants were analyzed, showing that etrolizumab significantly improved clinical response, remission, and various endoscopic outcomes compared to placebo, without increasing adverse events.
- The results suggest that etrolizumab is a promising treatment option for patients with IBD.
This study investigated that dieckol (DKL), a natural drug, inhibits colon cancer cell proliferation and migration by inhibiting phosphoinositide-3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) phosphorylation in HCT-116 cells. The cells were treated with DKL in various concentrations (32 and 50 μM) for 24 h and then analyzed for various experiments. MTT (tetrazolium bromide) and crystal violet assay investigated DKL-mediated cytotoxicity.
View Article and Find Full Text PDF